Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14328
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pingaew R. | |
dc.contributor.author | Prachayasittikul S. | |
dc.contributor.author | Ruchirawat S. | |
dc.contributor.author | Prachayasittikul V. | |
dc.date.accessioned | 2021-04-05T03:34:12Z | - |
dc.date.available | 2021-04-05T03:34:12Z | - |
dc.date.issued | 2012 | |
dc.identifier.issn | 2536269 | |
dc.identifier.other | 2-s2.0-84864915962 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14328 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864915962&doi=10.1007%2fs12272-012-0601-1&partnerID=40&md5=cd874f5e13565eacb3e914a762be1583 | |
dc.description.abstract | Tungstosilicic acid hydrate was employed as an efficient catalyst for the synthesis of bisindolylmethanes 4 using the Friedel-Crafts reaction of N-sulfonyl tryptamine 5 with various aromatic aldehydes, except 3-formylindole. In the excluding case, tris-indolylmethane 7 was formed via a sequential addition-elimination-addition process. The bioactivity test revealed that the phenolic hydroxyl group plays an important role in cytotoxicity; it demonstrated that ortho- and para-hydroxy bis-indolylmethane (BIM) analogs (4b and 4d) displayed cytotoxic potency toward HepG2 (human hepatocellular liver carcinoma cell line) and MOLT-3 (human lymphoblastic leukemia cell line) cancer cell lines. Significantly, both analogs showed slightly higher inhibitory efficacy than the control drug, etoposide, in HepG2 cells, and the analog 4d exhibited the most potent activity against MOLT-3 cell lines, with an IC50 value of 1.62 μg/mL. | |
dc.subject | antineoplastic agent | |
dc.subject | bis indolylmethane | |
dc.subject | carboline derivative | |
dc.subject | doxorubicin | |
dc.subject | etoposide | |
dc.subject | silicic acid | |
dc.subject | tris indolylmethane | |
dc.subject | tungstosilicic acid hydrate | |
dc.subject | unclassified drug | |
dc.subject | addition reaction | |
dc.subject | article | |
dc.subject | cell strain HepG2 | |
dc.subject | cell survival | |
dc.subject | controlled study | |
dc.subject | cytotoxicity | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | elimination reaction | |
dc.subject | Friedel Crafts reaction | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | IC 50 | |
dc.subject | Antineoplastic Agents | |
dc.subject | Carbolines | |
dc.subject | Cell Survival | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Etoposide | |
dc.subject | Hep G2 Cells | |
dc.subject | Humans | |
dc.subject | Indoles | |
dc.subject | Inhibitory Concentration 50 | |
dc.subject | Molecular Structure | |
dc.title | Synthesis and cytotoxicity of novel 2,2'-Bis- and 2,2',2''-Tris-indolyl- methanes-based bengacarboline analogs | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Archives of Pharmacal Research. Vol 35, No.6 (2012), p.949-954 | |
dc.identifier.doi | 10.1007/s12272-012-0601-1 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.